



45  
w/cont

**PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

**In re Application of:**

Van Leengoed et al.

**Serial No.:** 09/202,104

**Filed:** June 19, 1997

**For:** IL-6 AND IL-6-RECEPTOR  
DERIVED PEPTIDES HAVING IL-6  
ANTAGONISTIC OR AGONISTIC  
ACTIVITY

**Examiner:** Unknown

**Group Art Unit:** Unknown

**Attorney Docket No.:** 3890US

**CERTIFICATE OF MAILING**

I hereby certify that this correspondence along with any attachments referred to or identified as being attached or enclosed is being deposited with the United States Postal Service as First Class Mail (under 37 C.F.R. § 1.8(a)) on the date of deposit shown below with sufficient postage and in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

7/13/99  
Date of Deposit

*Darlene Holt*  
Signature of registered practitioner or other person  
having reasonable basis to expect mailing to occur  
on date of deposit shown pursuant to 37 C.F.R. §  
1.8(a)(1)(ii)

Darlene Holt  
Typed/printed name of person whose signature is  
contained above

**INFORMATION DISCLOSURE STATEMENT**

Box NON-FEE

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

In compliance with the duty to disclose information material to patentability pursuant to 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents are enclosed pursuant to 37 C.F.R. § 1.98(a).

In accordance with 37 C.F.R. § 1.97(g) and (h), filing of this Information Disclosure Statement is not to be construed as a representation that a search has been made or an admission that the information cited herein is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b). Further, no representation is made by Applicants herein that no other possible material information as defined in 37 C.F.R. § 1.56(b) exists.

DOCUMENTS

U.S. Patent Documents

<u>U.S. Patent No.</u>	<u>Issue Date</u>	<u>Inventor</u>
5,210,075	05/1993	Scholz et al.

Foreign Patent Documents

<u>Document No.</u>	<u>Date</u>	<u>Country</u>
0 426 857 A1	08/1990	EP
WO 95/04075	02/1995	PCT

Other Documents


Kalai, M., et al., *Participation of two Ser-Ser-Phe-Tyr repeats in interleukin-6 (IL-6)-binding sites of the human IL-6 receptor*, Eur. J. Biochem. 238:714-723 (1996).

Morton, C.J., et al., *Solution structure of synthetic peptides corresponding to the C-terminal helix of interleukin-6*, pages 97-107 (undated).

This Information Disclosure Statement is believed to be filed before the mailing date of the first Office Action on the merits in the above-identified application.

Applicants offer to supply any explanation or discussion of the documents which the Examiner feels is necessary or desirable and which is requested.

Respectfully submitted,

  
Laurence B. Bond  
Registration No. 30,549  
Attorney for Applicants  
TRASK, BRITT & ROSSA  
P. O. Box 2550

Salt Lake City, Utah 84110-2550  
Telephone: (801) 532-1922

Date: July 8, 1999

LBB/jml

Enclosures: Form PTO-1449

Copy of documents cited

NA2183\3890\IDS.wpd 7/8/99